Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics is currently on track with its clinical trials and development of ficerafusp alfa, which has the potential to be a transformative therapy for patients with solid tumors. With additional data from trials expected in 2026, as well as plans for an interim analysis in 2027, the company has potential catalysts for future growth. However, in the bear case scenario, underwhelming clinical results and limited differentiation could lower the probability of success for ficerafusp alfa, resulting in a lower fair value of $11. The stock's closing price over the past 12 months and projected prices in bull, base, and bear cases suggest potential upside for investors.

Bears say

Bicara Therapeutics is facing a highly competitive landscape in the 3L+ MSS mCRC market, with several early-stage programs showing promising efficacy and durability data. Bicara's hybrid antibody, ficerafusp alfa, is being positioned as a potential solution to this challenge, based on its dual EGFR/TGF-b inhibition mechanism. However, there are concerns around the safety profile of ficerafusp alfa, particularly in long-term maintenance use. The bull scenario for Bicara hinges on its ability to prove the efficacy and safety of ficerafusp alfa in various treatment contexts, which could result in significant market share and a $42 fair value for the company.

BCAX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 9 analysts, BCAX has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.